{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:41:25Z","timestamp":1788900085205,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["U01AR071693"],"award-info":[{"award-number":["U01AR071693"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001117"],"award-info":[{"award-number":["UL1TR001117"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ymthe.2023.02.014","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T22:55:36Z","timestamp":1676847336000},"page":"1994-2004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Phase I study of liver depot gene therapy in late-onset Pompe disease"],"prefix":"10.1016","volume":"31","author":[{"given":"Edward C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crista","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dearmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-oh","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy G.","family":"Spears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Chichester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward H.","family":"Bossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-2464","authenticated-orcid":false,"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.02.014_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/ijns6040089","article-title":"Newborn screening for pompe disease: Pennsylvania experience","volume":"6","author":"Ficicioglu","year":"2020","journal-title":"Int. J. Neonatal. Screen."},{"key":"10.1016\/j.ymthe.2023.02.014_bib2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymgme.2016.05.015","article-title":"Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry","volume":"118","author":"Elliott","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2023.02.014_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2023.02.014_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2023.02.014_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib6","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2023.02.014_bib7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2023.02.014_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00455-009-9252-x","article-title":"Oropharyngeal dysphagia in infants and children with infantile Pompe disease","volume":"25","author":"Jones","year":"2010","journal-title":"Dysphagia"},{"key":"10.1016\/j.ymthe.2023.02.014_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3928\/01913913-20100106-08","article-title":"Clinical and histologic ocular findings in Pompe disease","volume":"47","author":"Yanovitch","year":"2010","journal-title":"J.\u00a0Pediatr. Ophthalmol. Strabismus"},{"key":"10.1016\/j.ymthe.2023.02.014_bib12","first-page":"621","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2023.02.014_bib13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2023.02.014_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2008.010","article-title":"Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice","volume":"19","author":"Ziegler","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib17","doi-asserted-by":"crossref","first-page":"103737","DOI":"10.1016\/j.cellimm.2017.12.011","article-title":"Immunomodulatory, liver depot gene therapy for Pompe disease","volume":"342","author":"Bond","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2023.02.014_bib18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.02.014_bib19","doi-asserted-by":"crossref","first-page":"14018","DOI":"10.1038\/mtm.2014.18","article-title":"Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease","volume":"1","author":"Wang","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.02.014_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/hum.2021.252","article-title":"Minimum effective dose to achieve biochemical correction with AAV vector-mediated gene therapy in mice with Pompe disease","volume":"33","author":"Han","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib21","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy","volume":"16","author":"Sun","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1089\/hum.2011.063","article-title":"Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease","volume":"23","author":"Zhang","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib24","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/mt.2016.61","article-title":"Superior in\u00a0vivo transduction of human hepatocytes using engineered AAV3 capsid","volume":"24","author":"Vercauteren","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2023.02.014_bib27","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of biochemical abnormalities and improved muscle function in a phase I\/II clinical trial of clenbuterol in pompe disease","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1096\/fj.12-207472","article-title":"Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2023.02.014_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/hum.2021.218","article-title":"Efficacious androgen hormone administration in combination with AAV vector-mediated gene therapy in female mice with Pompe disease","volume":"33","author":"Han","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/hum.2018.197","article-title":"Salmeterol with liver depot gene therapy enhances the skeletal muscle response in murine Pompe disease","volume":"30","author":"Han","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib33","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ymgme.2022.01.003","article-title":"Early clinical phenotype of late onset Pompe disease: lessons learned from newborn screening","volume":"135","author":"Huggins","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2023.02.014_bib34","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMe1111138","article-title":"Merry christmas for patients with hemophilia B","volume":"365","author":"Ponder","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s41669-019-0142-3","article-title":"A systematic review of the health economics of pompe disease","volume":"3","author":"Schoser","year":"2019","journal-title":"Pharmacoecon. Open"},{"key":"10.1016\/j.ymthe.2023.02.014_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2023.02.014_bib37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib38","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2023.02.014_bib39","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus types 1, 2, 5, 6, 8 and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib41","doi-asserted-by":"crossref","first-page":"442.e35","DOI":"10.1111\/ene.13835","article-title":"Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis","volume":"26","author":"Musumeci","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymthe.2023.02.014_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1152\/jn.00190.2021","article-title":"Case Studies in Neuroscience: neuropathology and diaphragm dysfunction in ventilatory failure from late-onset Pompe disease","volume":"126","author":"Fuller","year":"2021","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.ymthe.2023.02.014_bib43","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.02.014_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40478-017-0464-2","article-title":"Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease","volume":"5","author":"Hordeaux","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ymthe.2023.02.014_bib45","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","article-title":"The respiratory neuromuscular system in Pompe disease","volume":"189","author":"Fuller","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.ymthe.2023.02.014_bib47","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.02.014_bib48","doi-asserted-by":"crossref","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.resp.2016.02.007","article-title":"Neuropathology in respiratory-related motoneurons in young Pompe (Gaa(-\/-)) mice","volume":"227","author":"Turner","year":"2016","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.ymthe.2023.02.014_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/hmg\/ddu476","article-title":"Peripheral nerve and neuromuscular junction pathology in Pompe disease","volume":"24","author":"Falk","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2023.02.014_bib51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous injection of an AAV-PHP.B vector encoding human acid alpha-glucosidase rescues both muscle and cns defects in murine Pompe disease","volume":"12","author":"Lim","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.02.014_bib52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/hgtb.2018.038","article-title":"Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors","volume":"29","author":"Calcedo","year":"2018","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2023.02.014_bib53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2023.02.014_bib54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mus.880060204","article-title":"Clinical investigation in Duchenne dystrophy: 2. Determination of the \"power\" of therapeutic trials based on the natural history","volume":"6","author":"Brooke","year":"1983","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2023.02.014_bib55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","article-title":"Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease","volume":"104","author":"van der Beek","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2023.02.014_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:08:01Z","timestamp":1761502081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1525001623000771"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.014","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of liver depot gene therapy in late-onset Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}